DBV Technologies (NASDAQ:DBVT) Now Covered by Analysts at StockNews.com

Research analysts at StockNews.com initiated coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research note issued on Tuesday. The brokerage set a “hold” rating on the stock.

DBVT has been the subject of several other reports. HC Wainwright lifted their price target on shares of DBV Technologies from $25.00 to $35.00 and gave the company a “buy” rating in a report on Thursday, October 24th. JMP Securities reissued a “market outperform” rating and set a $10.00 price objective on shares of DBV Technologies in a report on Tuesday, December 10th.

DBV Technologies Trading Up 3.4 %

DBVT opened at $3.30 on Tuesday. The stock has a market capitalization of $67.88 million, a price-to-earnings ratio of -0.73 and a beta of 0.64. The business has a 50 day moving average of $3.43 and a 200-day moving average of $3.96. DBV Technologies has a 1-year low of $2.20 and a 1-year high of $10.70.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.